Combining ADCs with protein degraders could widen the therapeutic windows of both

Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge

BioCentury | Mar 12, 2022

Discovery & Translation

Translational highlights to watch for at AACR

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference

Items per page:

1 - 2 of 2